Opdivo

milestone milestone pharmaceuticals

Pharma

Huyabio's HDAC inhibitor scores in phase 3 melanoma study

Huyabio's HDAC inhibitor HBI-8000 has succeeded in combo with Bristol Myers Squibb’s Opdivo in a phase 3 trial of patients with advanced skin cancer.

Kevin Dunleavy Jul 14, 2026 10:48am

FDA Building

FDA limits Keytruda, Opdivo uses in stomach cancer

Jun 9, 2025 10:50am

Opdualag

ASCO: Bristol CMO brushes off LAG-3 concern after melanoma flop

Jun 3, 2025 8:00am

BMS

BMS follows Roche, AstraZeneca into first-line liver cancer

Apr 11, 2025 1:53pm

Exelixis

Exelixis shifts focus as triplet misses OS mark in kidney cancer

Feb 18, 2025 1:30pm

BMS

BMS’ Opdualag flunks trial as adjuvant for resected melanoma

Feb 14, 2025 8:15am